Reagenti e strumenti per immunologia, biologia cellulare e biologia molecolare
 
> Ruxolitinib (S enantiomer) [941685-37-6]

Ruxolitinib (S enantiomer) [941685-37-6]

Stampa Stampa
Entra

Cat# HY-50856A-5mg

Size : 5mg

Marca : MedChemExpress

Richiedere ulteriori informazioni

Contatta il distributore locale :


Telefono : +1 850 650 7790

Description

Ruxolitinib (S enantiomer) (S-Ruxolitinib) is the S-enantiomer of Ruxolitinib (HY-50856). Ruxolitinib (S enantiomer) is an orally active, potent JAK inhibitor[1][2].

IC50 & Target

JAK

 

In Vitro

Ruxolitinib (S enantiomer) (S-Ruxolitinib; 10 μM; 12 hours) suppresses IFNβ-induced expression of ISG, IFIT, and IFITM[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Ruxolitinib (S enantiomer) Related Antibodies

RT-PCR[1]

Cell Line: Human small airway epithelial cells (SAECs)
Concentration: 10 μM
Incubation Time: 12 hours
Result: Suppressed IFNβ-induced expression of ISG, IFIT, and IFITM.
In Vivo

Ruxolitinib (S enantiomer) (S-Ruxolitinib; 30 mg/kg; Oral gavage; twice per day separated 10-12 h for 8 weeks) reduces haematopoietic cell expansion in MPN[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Female wild-type C57BL/6J or Nes-gfp27 mice with myeloproliferative neoplasms (MPNs) in peripheral blood[2]
Dosage: 30 mg/kg (in 0.5% hydroxypropylmethylcellulose after solubilisation in DMSO)
Administration: Oral gavage; twice per day separated 10-12 h for 8 weeks
Result: Reduced haematopoietic cell expansion in MPN but it did not rescue bone marrow (BM) mesenchymal stem cells (MSCs).
Masse moléculaire

306.37

Formule

C17H18N6
CAS No.
Appearance

Solid

Color

White to off-white

SMILES

N#CC[C@@H](C1CCCC1)N2N=CC(C3=NC=NC4=C3C=CN4)=C2
Livraison

Room temperature in continental US; may vary elsewhere.
Stockage
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 2 years
-20°C 1 year
Solvant et solubilité
In Vitro: 

DMSO : ≥ 100 mg/mL (326.40 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

1M HCl : 50 mg/mL (163.20 mM; ultrasonic and adjust pH to 1 with HCl)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 3.2640 mL 16.3201 mL 32.6403 mL
5 mM 0.6528 mL 3.2640 mL 6.5281 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.5 mg/mL (8.16 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: ≥ 2.5 mg/mL (8.16 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

    Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Pureté et documentation
Références

Si può anche essere interessati nei seguenti prodotti:



Cat#
Descrizione
Cond.
Priced